Insight, China's Pharmaceutical Industry

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Grand Pharmaceutical Group Limited (HKG: 0512) announced a comprehensive strategic commercialization partnership with Siemens Healthineers...

Company Drug

GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood

Fineline Cube Jul 21, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted a...

Company Drug

Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention

Fineline Cube Jul 21, 2026

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its clinical trial application...

Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026

Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a...

Company Drug

Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment

Fineline Cube Jul 21, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) announced that...

Company Drug

Eisai and Biogen Secure FDA Approval for LEQEMBI Subcutaneous Autoinjector for Early Alzheimer’s Disease Initiation

Fineline Cube Jul 21, 2026

Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that the U.S....

Company Deals

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market

Fineline Cube Jul 21, 2026

Samsung Biologics (KRX: 207940) announced an all-cash bid of 1.46 billion Swiss francs (USD 1.8...

Company Deals

Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients

Fineline Cube Jul 21, 2026

Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable...

Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026

The National Joint Procurement Office (NJPO) has issued the Notice on Corporate Affiliations for the...

Company Deals

Hisun Pharmaceutical Secures Exclusive Rights to TISA-818 – Novel Multi-Target Immunomodulator for ARDS and Pulmonary Fibrosis

Fineline Cube Jul 21, 2026

Hisun Pharmaceutical (SHA: 600267) announced it has entered into an exclusive licensing agreement with EnliTISA...

Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Fineline Cube Jul 20, 2026

The Fujian Provincial Medical Security Bureau has implemented the “Ten Measures to Support the Innovative...

Policy / Regulatory

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

Fineline Cube Jul 20, 2026

China’s National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use...

Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Fineline Cube Jul 20, 2026

CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted...

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Fineline Cube Jul 20, 2026

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals,...

Company Drug

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

Fineline Cube Jul 20, 2026

Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has...

Company Drug

Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody

Fineline Cube Jul 20, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application...

Policy / Regulatory

China’s Health Authorities Issue Comprehensive Medical Equipment Centralized Procurement Framework with Tiered Implementation and High-Value Equipment Database

Fineline Cube Jul 20, 2026

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine (NATCM), and National Disease...

Company Drug

Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules – Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties

Fineline Cube Jul 20, 2026

Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam...

Company Drug

Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines

Fineline Cube Jul 20, 2026

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the European Commission has approved Boey...

Company Drug

GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short

Fineline Cube Jul 20, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III...

Insight, China's Pharmaceutical Industry

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood

Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment

Eisai and Biogen Secure FDA Approval for LEQEMBI Subcutaneous Autoinjector for Early Alzheimer’s Disease Initiation

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market

Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Hisun Pharmaceutical Secures Exclusive Rights to TISA-818 – Novel Multi-Target Immunomodulator for ARDS and Pulmonary Fibrosis

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody

China’s Health Authorities Issue Comprehensive Medical Equipment Centralized Procurement Framework with Tiered Implementation and High-Value Equipment Database

Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules – Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties

Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines

GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short

You Missed

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent